HRP20141185T1 - Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu - Google Patents
Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu Download PDFInfo
- Publication number
- HRP20141185T1 HRP20141185T1 HRP20141185TT HRP20141185T HRP20141185T1 HR P20141185 T1 HRP20141185 T1 HR P20141185T1 HR P20141185T T HRP20141185T T HR P20141185TT HR P20141185 T HRP20141185 T HR P20141185T HR P20141185 T1 HRP20141185 T1 HR P20141185T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- weight
- preparation according
- relation
- total weight
- Prior art date
Links
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title claims 10
- 229960004002 levetiracetam Drugs 0.000 title claims 10
- 238000000034 method Methods 0.000 title claims 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 48
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 239000011230 binding agent Substances 0.000 claims 10
- 239000000314 lubricant Substances 0.000 claims 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 8
- 235000019359 magnesium stearate Nutrition 0.000 claims 8
- 229910002027 silica gel Inorganic materials 0.000 claims 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 7
- 239000008119 colloidal silica Substances 0.000 claims 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000000454 talc Substances 0.000 claims 6
- 235000012222 talc Nutrition 0.000 claims 6
- 229910052623 talc Inorganic materials 0.000 claims 6
- 239000011248 coating agent Substances 0.000 claims 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims 5
- 238000005056 compaction Methods 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 3
- 235000021355 Stearic acid Nutrition 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 3
- 239000008116 calcium stearate Substances 0.000 claims 3
- 235000013539 calcium stearate Nutrition 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 229960001855 mannitol Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 229960002920 sorbitol Drugs 0.000 claims 3
- 239000008107 starch Substances 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 239000008117 stearic acid Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 229960004793 sucrose Drugs 0.000 claims 3
- 206010027654 Allergic conditions Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 201000006517 essential tremor Diseases 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229960001866 silicon dioxide Drugs 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (32)
1. Farmaceutski pripravak koji sadrži levetiracetam kao aktivni sastojak i 2.0 do 9.0% po težini dezintegriranog sredstva, naznačen time da je odabran iz skupine koju čine polivinilpolipirolidon, i natrijeva kroskarmeloza,
0.0 do 3.0% po težini klizno sredstvo, odabrano iz skupine koja se sastoji od talka, škroba, stearinske kiseline i anhidridnog koloidnog silikagela,
0.5 do 6.0% po težini vezivnog sredstva, odabranog iz skupine koja se sastoji od makrogola, mikrokristalne celuloze, saharoze, manitola i sorbitola, i
0.0 do 1.0% po težini sredstva za podmazivanje, odabranog iz skupine koja se sastoji od talka, magnezijevog stearata i kalcijevog stearata,
u odnosu na ukupnu težinu farmaceutskog pripravka.
2. Farmaceutski pripravak prema patentnom zahtjevu 1 naznačen time da sadrži 3.0 do 7.0% po težini dezintegriranog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
3. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 3.0 do 5.0% po težini dezintegriranog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
4. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.5 do 2.5% po težini kliznog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
5. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 1.0 do 2.0% po težini kliznog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
6. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.5 do 4.0 % po težini vezivnog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
7. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.5 do 2.5% po težini vezivnog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
8. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.7 do 1.8% po težini vezivnog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
9. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.8 to 1.6% po težini vezivnog sredstva u odnosu na ukupnu težinu farmaceutskog pripravka.
10. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.0 to 0.75% po težini sredstva za podmazivanje u odnosu na ukupnu težinu farmaceutskog pripravka.
11. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.0 to 0.50% po težini sredstva za podmazivanje u odnosu na ukupnu težinu farmaceutskog pripravka.
12. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.05 to 0.25% po težini sredstva za podmazivanje u odnosu na ukupnu težinu farmaceutskog pripravka.
13. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.08 to 0.15% po težini sredstva za podmazivanje u odnosu na ukupnu težinu farmaceutskog pripravka.
14. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da je dezintegrirano sredstvo natrijeva kroskarmeloza.
15. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da je klizno sredstvo anhidrirani koloidni silikagel.
16. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da je vezivno sredstvo polietilen glikol 6000.
17. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da je sredstvo za podmazivanje magnezijev stearat.
18. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 2.0 do 9.0% po težini natrijeve kroskarmeloze u odnosu na ukupnu težinu farmaceutskog pripravka.
19. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.0 do 3.0% po težini anhidriranog koloidnog silikagala u odnosu na ukupnu težinu farmaceutskog pripravka.
20. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.5 do 6.0% po težini polietilen glikola 6000 u odnosu na ukupnu težinu farmaceutskog pripravka.
21. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 0.0 do 1.0% po težini magnezijevog stearata u odnosu na ukupnu težinu farmaceutskog pripravka.
22. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži 80 % do 95% po težini levetiracetama.
23. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da sadrži sredstvo za oblaganje.
24. Farmaceutski pripravak prema patentnom zahtjevu 23 naznačen time da sredstvo za oblaganje sadrži polivinil alkohol.
25. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 23 i 24 naznačen time da je sredstvo za oblaganje vodena disperzija hidroksi-propilmetilceluloze.
26. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je tableta.
27. Proces za proizvodnju farmaceutskog pripravka koji sadrži levetiracetam kao aktivni sastojak i
2,0 do 9,0% po težini dezintegriranog sredstva, naznačen time da je odabran iz skupine koju čine polivinilpirolidon, i natrijeva kroskarmeloza,
0 do 3.0% po težini kliznog sredstva, odabranog iz skupine koju čine talk, škrob, stearinska kiselina i anhidrirani koloidni silikagel,
0.5 do 6.0% po težini vezivnog sredstva, odabranog iz skupine koju čine makrogoli, mikrokristalna celuloza, saharoza, manitol i sorbitol, i
0.0 do 1.0% po težini sredstva za podmazivanje, odabranog iz skupine koju čine talk, magnezijev stearat i kalcijev stearat,
u odnosu na ukupnu težinu farmaceutskog pripravka,
koji proces obuhvaća sljedeće korake:
i) miješanje levetiracetama, kliznog sredstva, dezintegriranog sredstva i vezivnog sredstva,
ii) dodavanje sredstva za podmazivanje,
iii) miješanje levetiracetama, kliznog sredstva, dezintegriranog sredstva i vezivnog sredstva za i sredstva za podmazivanje;
iv) zbijanje smjese dobivene u koraku iii) ,
v) mljevenje smjese dobivene u koraku iv), i
vi) sabijanje smjese dobivene u koraku v).
28. Proces za proizvodnju farmaceutskog pripravka prema patentnom zahtjevu 27 naznačen time da sadrži levetiracetam kao aktivni sastojak i
2.0 do 9.0% po težini natrijeve kroskarmeloze,
0.0 do 3.0% po težini anhidriranog koloidnog silikagela,
0.5 do 6.0% po težini polietilen glikola 6000, i
0.0 do 1.0% po težini magnezijevog stearata,
u odnosu na ukupnu težinu farmaceutskog pripravka,
koji proces obuhvata sljedeće korake:
i) miješanje levetiracetama, anhidriranog koloidnog silikagela, natrijeve kroskarmeloze, polietilen glikola 6000,
ii) dodavanje magnezijevog stearata,
iii) miješanje levetiracetama anhidriranog koloidnog silikagela, natrijeve kroskarmeloze, polietilen glikola 6000, i magnezijevog stearata;
iv) zbijanje smjese dobivene u koraku iii),
v) mljevenje smjese dobivene u koraku iv), i
vi) sabijanje smjese dobivene u koraku v).
29. Proces prema patentnom zahtjevu 28 naznačen time da uključuje raspršivanja na smjesu dobivenu u koraku vi), sredstva za oblaganje koje je suspenzija hidroksipropilmetilceluloze.
30. Proces prema zahtjevu 29 naznačen time da sredstvo za oblaganje sadrži polivinilalkohol.
31. Farmaceutski pripravak koji sadrži levetiracetam i 2.0 do 9.0% po težini dezintegriranog sredstva, naznačen time da je odabran iz skupine koju čine polivinilpolipirolidon, i natrijeva kroskarmeloza,
0 do 3.0% po težini kliznog sredstva, odabranog iz skupine koju čine talk, škrob, stearinska kiselina i anhidrirani koloidi silikagel,
0.5 do 6.0% po težini vezivnog sredstva, odabrano iz skupine koju čine makrogoli, mikrokristalna celuloza, saharoza, manitol, i sorbitol, i
0.0 do 1.0% po težini sredstva za podmazivanje, odabranog iz skupine koju čine talk, magnezijev stearat i kalcijev stearat,
u odnosu na ukupnu težinu farmaceutskog pripravka za upotrebu u liječenju epilepsije, Parkinsonove bolesti, diskinezije, migrene, tremora, esencijalnog tremora, bipolarnog poremećaja, kronične boli, neuropatske boli ili bronhijalnog, astmatičnog ili alergijskog stanja.
32. Upotreba farmaceutskog pripravka prema bilo kojem od prethodnih patentnih zahtjeva 1 do 26 za proizvodnju lijeka za liječenje epilepsije, Parkinsonove bolesti, diskinezije, migrene, tremora, esencijalnog tremora, bipolarnig poremećaja, kronične boli, neuropatske boli, ili bronhijalnog, astmatičnog ili alergijskog stanja.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05016189 | 2005-07-26 | ||
| EP05016945 | 2005-08-04 | ||
| PCT/EP2006/007260 WO2007012439A1 (en) | 2005-07-26 | 2006-07-24 | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
| EP06776372.2A EP1909764B1 (en) | 2005-07-26 | 2006-07-24 | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141185T1 true HRP20141185T1 (hr) | 2015-01-30 |
Family
ID=36888840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141185TT HRP20141185T1 (hr) | 2005-07-26 | 2014-12-08 | Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8802142B2 (hr) |
| EP (1) | EP1909764B1 (hr) |
| JP (2) | JP5183470B2 (hr) |
| KR (1) | KR20080030546A (hr) |
| CN (1) | CN101068534B (hr) |
| AR (1) | AR054581A1 (hr) |
| AU (1) | AU2006274263B2 (hr) |
| BR (1) | BRPI0606121A2 (hr) |
| CA (1) | CA2581831C (hr) |
| CY (1) | CY1115825T1 (hr) |
| DK (1) | DK1909764T3 (hr) |
| EA (1) | EA014961B1 (hr) |
| ES (1) | ES2524771T3 (hr) |
| HK (1) | HK1109071A1 (hr) |
| HR (1) | HRP20141185T1 (hr) |
| IL (1) | IL182375A0 (hr) |
| MX (1) | MX2007004294A (hr) |
| NO (1) | NO20071667L (hr) |
| NZ (1) | NZ554157A (hr) |
| PE (2) | PE20070216A1 (hr) |
| PL (1) | PL1909764T3 (hr) |
| PT (1) | PT1909764E (hr) |
| RS (1) | RS53690B1 (hr) |
| SI (1) | SI1909764T1 (hr) |
| TW (1) | TW200738280A (hr) |
| WO (1) | WO2007012439A1 (hr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE05815688T1 (de) | 2005-01-27 | 2008-06-26 | Alembic Ltd. | Levetiracetam-formulierung mit verlängerter freisetzung |
| CA2637925A1 (en) * | 2006-01-24 | 2007-08-02 | Teva Pharmaceutical Industries Ltd. | Levetiracetam formulations and methods for their manufacture |
| FR2912056B1 (fr) * | 2007-02-05 | 2009-12-18 | Rd Pharmagal | Composition a liberation prolongee de levetiracetam et procede de preparation |
| JP2010024156A (ja) * | 2008-07-16 | 2010-02-04 | Ucb Pharma Sa | レベチラセタムを含む医薬組成物 |
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| CN101422442A (zh) * | 2008-12-09 | 2009-05-06 | 沈阳药科大学 | 左乙拉西坦渗透泵控释片及其制备方法 |
| US20100159009A1 (en) * | 2008-12-24 | 2010-06-24 | Zhongshui Yu | Controlled-release formulations |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| ES2511047T3 (es) * | 2009-01-29 | 2014-10-22 | Ucb Pharma, S.A. | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina |
| DK2445570T3 (da) | 2009-06-26 | 2013-02-25 | Taris Biomedical Inc | Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling |
| CN102038657B (zh) * | 2009-10-10 | 2015-04-15 | 浙江华海药业股份有限公司 | 左乙拉西坦片及其制备方法 |
| CA2789307A1 (en) * | 2010-03-29 | 2011-10-06 | Hetero Research Foundation | Stable pharmaceutical composition of imatinib |
| TR201011148A1 (tr) | 2010-12-30 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Levetirasetam farmasötik bileşimleri. |
| EP3400934A1 (en) * | 2011-02-09 | 2018-11-14 | The Johns Hopkins University | Levetiracetam for improving cognitive function |
| CN102188420B (zh) * | 2011-03-25 | 2013-04-10 | 华润赛科药业有限责任公司 | 一种左乙拉西坦的药物组合物及其制备方法 |
| CN102871981B (zh) * | 2012-10-25 | 2013-11-13 | 杭州朱养心药业有限公司 | 包含左乙拉西坦的片剂药物组合物 |
| CN102895214B (zh) * | 2012-10-25 | 2014-03-26 | 杭州朱养心药业有限公司 | 左乙拉西坦片剂的固体药物组合物 |
| CN103127175B (zh) * | 2013-02-22 | 2014-01-22 | 张晓光 | 一种抗癫痫药物及其制备方法 |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| MX365513B (es) | 2013-03-15 | 2019-06-06 | Aprecia Pharmaceuticals LLC | Forma de dosificacion de dispersion rapida que contiene levetiracetam. |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US20170035733A1 (en) * | 2013-11-29 | 2017-02-09 | Ucb Pharma Gmbh | Pharmaceutical composition comprising lacosamide and levetiracetam |
| CN104666263B (zh) * | 2015-02-09 | 2017-07-11 | 海南华益泰康药业有限公司 | 一种含有左乙拉西坦的片剂及其制备方法 |
| CA2986598C (en) * | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| JP6630229B2 (ja) * | 2016-05-17 | 2020-01-15 | エルメッド株式会社 | レベチラセタム含有医薬組成物及びその製造方法 |
| JP6422464B2 (ja) * | 2016-05-19 | 2018-11-14 | エルメッド エーザイ株式会社 | レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤 |
| CN107913258A (zh) * | 2016-10-09 | 2018-04-17 | 北京阜康仁生物制药科技有限公司 | 一种左乙拉西坦缓释片及其制备方法 |
| JP6326114B2 (ja) * | 2016-11-01 | 2018-05-16 | エルメッド エーザイ株式会社 | レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤 |
| JP7264711B2 (ja) * | 2019-04-26 | 2023-04-25 | 東和薬品株式会社 | レベチラセタム含有医薬組成物の製造方法 |
| JP7575217B2 (ja) | 2019-08-09 | 2024-10-29 | 日本ジェネリック株式会社 | レベチラセタムを含む錠剤 |
| CN117838643A (zh) * | 2023-12-29 | 2024-04-09 | 山东力诺制药有限公司 | 一种吡拉西坦片及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| EP0618983B1 (en) * | 1992-10-09 | 1999-09-01 | VYSIS, Inc. | Insertion elements and amplifiable nucleic acids |
| BE1011045A3 (fr) | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| IL149530A0 (en) | 1999-12-01 | 2002-11-10 | Ucb Sa | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| DE60204224T2 (de) * | 2001-03-22 | 2006-02-02 | Ucb S.A. | Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen |
| WO2003094913A1 (en) * | 2002-05-14 | 2003-11-20 | Ucb, S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug |
| JP2006516390A (ja) | 2002-12-03 | 2006-07-06 | ユ セ ベ ソシエテ アノニム | 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法 |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| CN1802352A (zh) * | 2003-02-03 | 2006-07-12 | 特瓦制药工业有限公司 | 制备左乙拉西坦的方法 |
| CA2526562C (en) * | 2003-05-23 | 2011-06-28 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| DE05815688T1 (de) | 2005-01-27 | 2008-06-26 | Alembic Ltd. | Levetiracetam-formulierung mit verlängerter freisetzung |
-
2006
- 2006-07-24 PE PE2006000890A patent/PE20070216A1/es not_active Application Discontinuation
- 2006-07-24 TW TW095126931A patent/TW200738280A/zh unknown
- 2006-07-24 US US11/910,167 patent/US8802142B2/en active Active
- 2006-07-24 PL PL06776372T patent/PL1909764T3/pl unknown
- 2006-07-24 MX MX2007004294A patent/MX2007004294A/es active IP Right Grant
- 2006-07-24 CN CN2006800012799A patent/CN101068534B/zh active Active
- 2006-07-24 EP EP06776372.2A patent/EP1909764B1/en not_active Revoked
- 2006-07-24 PT PT67763722T patent/PT1909764E/pt unknown
- 2006-07-24 AU AU2006274263A patent/AU2006274263B2/en not_active Ceased
- 2006-07-24 PE PE2010000095A patent/PE20100265A1/es not_active Application Discontinuation
- 2006-07-24 SI SI200631863T patent/SI1909764T1/sl unknown
- 2006-07-24 NZ NZ554157A patent/NZ554157A/en not_active IP Right Cessation
- 2006-07-24 CA CA2581831A patent/CA2581831C/en not_active Expired - Fee Related
- 2006-07-24 ES ES06776372.2T patent/ES2524771T3/es active Active
- 2006-07-24 DK DK06776372.2T patent/DK1909764T3/da active
- 2006-07-24 BR BRPI0606121-4A patent/BRPI0606121A2/pt not_active Application Discontinuation
- 2006-07-24 KR KR1020077007855A patent/KR20080030546A/ko not_active Application Discontinuation
- 2006-07-24 WO PCT/EP2006/007260 patent/WO2007012439A1/en active Application Filing
- 2006-07-24 EA EA200700566A patent/EA014961B1/ru not_active IP Right Cessation
- 2006-07-24 JP JP2008523207A patent/JP5183470B2/ja active Active
- 2006-07-24 RS RS20140675A patent/RS53690B1/en unknown
- 2006-07-25 AR ARP060103193A patent/AR054581A1/es not_active Application Discontinuation
-
2007
- 2007-03-29 NO NO20071667A patent/NO20071667L/no not_active Application Discontinuation
- 2007-04-01 IL IL182375A patent/IL182375A0/en unknown
- 2007-12-31 HK HK07114329.6A patent/HK1109071A1/xx unknown
-
2012
- 2012-10-12 JP JP2012226516A patent/JP2013018786A/ja active Pending
-
2014
- 2014-12-08 HR HRP20141185TT patent/HRP20141185T1/hr unknown
- 2014-12-10 CY CY20141101026T patent/CY1115825T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141185T1 (hr) | Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu | |
| AU2010215646B2 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| CA2722093C (en) | Pharmaceutical compositions comprising brivaracetam | |
| JP5750847B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
| AU2010209790B2 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| HRP20100674T1 (hr) | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka | |
| EP2043615A2 (en) | Pharmaceutical compositions comprising levetiracetam | |
| CA2696977A1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
| CN105377303B (zh) | 口腔崩解片 | |
| CA2895881A1 (en) | Tablet composition comprising cinacalcet hydrochloride | |
| HRP20191669T1 (hr) | Farmaceutski sastav koji sadrži polimer koji veže fosfate | |
| US20230022228A1 (en) | Pharmaceutical composition comprising eltrombopag bis(monoethanolamine) | |
| JP2014070061A5 (hr) | ||
| EP3335700A1 (de) | Feste pharmazeutische orale darreichungsform mit verlängerter wirkstofffreisetzung umfassend mirabegron | |
| CN102871981A (zh) | 包含左乙拉西坦的片剂药物组合物 |